On Oct. 10, 2022, Novavax announced that partner, SK bioscience, had submitted a Post Approval Change Application to the Korean Ministry of Food and Drug Safety for Nuvaxovidﾙ (NVX-CoV2373) COVID-19 vaccine for use as a heterologous and homologous booster for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults aged 18 and older. In September 2022, the Korean Centers for Disease Control and Prevention advised that Nuvaxovid can be used off-label as a booster in adults aged 18 and older.